Table 1.
Baseline characteristics of patients by study and symptom duration group
| |
Pooled data |
Etanercept |
Adalimumab |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
<4 years |
≥4 years |
P
-value |
<4 years |
≥4 years |
P
-value |
<4 years |
≥4 years |
P
-value |
|
| n = 58 | n = 54 | n = 42 | n = 24 | n = 16 | n = 30 | |||||
| Symptom duration mean (SD) |
2 (1.1) |
7.7 (5) |
|
2 (1.1) |
5.2 (0.9) |
|
1.9 (1) |
9.7 (5.9) |
|
|
| Age, years, mean (SD) |
31.7 (8.1) |
37.8 (8.4) |
0.001 |
31.6 (8.2) |
37 (7.7) |
0.01 |
31.8 (8.1) |
38.5 (9.1) |
0.02 |
|
| Male, n (%) |
30 (51.7) |
28 (51.9) |
0.99 |
25 (59.5) |
12 (50) |
0.45 |
5 (31.3) |
16 (53.3) |
0.15 |
|
| HLA-B27-positive, n (%) |
45 (77.6) |
41 (75.9) |
0.84 |
33 (78.6) |
22 (91.7) |
0.17 |
12 (75) |
19 (63.3) |
0.42 |
|
| Joints with arthritis, mean (SD) |
1.1 (3.3) |
1.7 (6.4) |
0.30 |
1.4 (3.9) |
1.9 (6) |
0.33 |
0.4 (0.7) |
1.6 (6.7) |
0.86 |
|
| Joints with enthesitis, mean (SD) |
2.5 (3.6) |
3.5 (3.8) |
0.095 |
2.7 (4) |
3.7 (4.6) |
0.41 |
2 (2.7) |
3.3 (3.1) |
0.16 |
|
| BASDAI, mean (SD) |
4.9 (1.9) |
6 (1.8) |
0.004 |
5 (1.7) |
5.5 (2) |
0.29 |
4.7 (2.4) |
6.3 (1.5) |
0.009 |
|
| BASFI, mean (SD) |
3.8 (2.4) |
5 (2.1) |
0.007 |
3.9 (2.2) |
4.4 (2.3) |
0.34 |
3.6 (2.8) |
5.4 (1.9) |
0.01 |
|
| BASMI mean (SD) |
1.5 (1.3) |
2.1 (1.8) |
0.057 |
1.7 (1.4) |
2.6 (2) |
0.04 |
1.1 (0.9) |
1.7 (1.6) |
0.16 |
|
| ASDAS, mean (SD) |
3.1 (0.9) |
3.1 (0.8) |
0.95 |
3.2 (0.8) |
3 (1) |
0.49 |
2.9 (0.9) |
3.2 (0.6) |
0.22 |
|
| CRP, mg/l, mean (SD) |
9 (9.3) |
6.9 (9.6) |
0.018 |
9.7 (10.4) |
8.8 (13.4) |
0.18 |
7.4 (6) |
5.4 (5.2) |
0.14 |
|
| log CRP, mg/l, mean (SD) |
2 (0.7) |
1.7 (0.8) |
0.018 |
2.1 (0.8) |
1.8 (0.8) |
0.26 |
1.9 (0.7) |
1.5 (0.8) |
0.16 |
|
| CRP-negative, n (%) |
26 (46.4) |
37 (71.2) |
0.009 |
18 (42.9) |
16 (66.7) |
0.04 |
8 (50) |
21 (70) |
0.18 |
|
| MRI SIJ score, mean (SD) | 6.2 (6.1) | 4.1 (4.7) | 0.08 | 6.4 (6) | 5 (5.7) | 0.21 | 5.4 (7) | 3.2 (3.4) | 0.61 | |
P-value <0.05 was taken to indicate statistically significant differences between two groups. HLA-B27, human leukocyte antigen-B27; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.